Metizolam is a thienodiazepine and a structural analog of diclazepam in which the benzene ring has been replaced with a thiophene ring — effectively making it the thienodiazepine equivalent of diclazepam. It produces typical benzodiazepine-like effects through positive allosteric modulation of GABA-A receptors: anxiolysis, sedation, muscle relaxation, and anticonvulsant activity. Metizolam emerged in research chemical markets in the early-to-mid 2010s and has generated a meaningful body of community discussion — eight Reddit posts in the database — with assessments ranging from enthusiastically positive to underwhelming relative to expectations.
Community experience with metizolam is notably mixed. Multiple posts describe it as "fantastic" and a "miracle molecule" for anxiety and social situations, while others characterize it as disappointing, inconsistent, or producing heavier sedation than anticipated. This variability in subjective reports is characteristic of compounds without extensive clinical characterization, where inter-individual differences in pharmacokinetics and setting effects are not averaged out by large sample sizes. Posts describing metizolam as useful for social anxiety and as producing a pleasant relaxed state contrast with accounts of unexpected drowsiness and limited anxiolytic effect.
One experience report in the database specifically documents a first-time use following alcohol consumption — a practice widely discouraged due to synergistic CNS depression risk. The report describes disappointment with the compound, which may reflect the blunting of perception from alcohol or the anxiolytic effect being less prominent than expected after prior alcohol intake. Despite the mixed reviews, metizolam carries the full risk profile of all benzodiazepine-class compounds: tolerance, physical dependence, potentially fatal withdrawal, and synergistic respiratory depression with other CNS depressants.
Safety at a Glance
High Risk- No Alcohol Combinations
- Moderate Frequency of Use
- Toxicity: Class Risk Profile Metizolam carries the standard benzodiazepine toxicity profile. Sole-agent use at typical doses is...
- Dangerous with: 1,4-Butanediol, 2M2B, Acetylfentanyl, Alcohol (+59 more)
- Overdose risk: overdose can be lethal when mixed with other depressants including alcohol or opioids. It is stro...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 5 hrs – 8 hrsHow It Feels
Metizolam introduces itself with the politeness of a substance that knows its place in the pharmacological hierarchy. Within thirty to forty-five minutes, a mild anxiolytic effect begins to manifest, arriving not as a wave but as a gentle adjustment to the emotional thermostat. The background hum of anxiety decreases by a few notches, and there is a subtle loosening of muscular tension that is easy to overlook unless you are paying careful attention. The overall impression is one of moderation -- this is a substance that aims to adjust rather than overwhelm.
As the come-up develops, the effects remain firmly in the mild-to-moderate range. The anxiolysis is real but gentle, a softening of the anxious edge rather than its elimination. The muscles relax modestly, and there is a light warmth in the body that promotes a general sense of comfort. The mind clears slightly as the background noise of worry diminishes, and there is a subtle improvement in mood -- not euphoria, but the quiet pleasure of reduced anxiety. Social situations feel slightly easier to navigate, the usual self-consciousness dialed down just enough to be noticeable. The sedation is light, a gentle drowsiness at the periphery of consciousness that does not impede function.
At the peak, metizolam delivers a steady, understated calm. The world feels slightly softer, slightly less demanding, and there is an emotional equanimity that makes it easier to take things as they come. Coordination remains largely intact, and cognitive function is preserved; this is a substance you can work through without difficulty. The muscle relaxation is pleasant but not profound, and the overall experience has a clean, uncomplicated quality. Memory is generally well-preserved, and there is no significant impairment of judgment or disinhibition. The experience is, in a word, manageable.
The offset is smooth and proportionate to the modest peak. Over three to five hours, the effects gradually diminish, the mild calm thinning back to baseline without any abrupt transitions. There is no notable rebound anxiety, no hangover, no residual fog. The overall impression metizolam leaves is one of a reliable minor anxiolytic -- pleasant enough in its effects but unlikely to command attention or demand repetition. It is the background music of the thienobenzodiazepine family: present, functional, and easily overlooked.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(6)
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Insomnia— A persistent inability to fall asleep or maintain sleep despite physical tiredness, often characteri...
- Muscle relaxation— The experience of muscles throughout the body losing their rigidity and tension, becoming noticeably...
- Respiratory depression— A dangerous slowing and shallowing of breathing that can progress from barely noticeable reductions ...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
Cognitive & Perceptual Effects
Cognitive(10)
- Amnesia— A complete or partial inability to form new memories or recall existing ones during and after substa...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Anxiety suppression— A partial to complete suppression of anxiety and general unease, producing a calm, relaxed mental st...
- Confusion— An impairment of abstract thinking marked by a persistent inability to grasp or comprehend concepts ...
- Delirium— Delirium is a serious and potentially dangerous state of acute mental confusion involving disorienta...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
- Disinhibition— A marked reduction in social inhibitions, self-consciousness, and behavioral restraint that manifest...
- Irritability— Irritability is a sustained state of emotional reactivity in which the threshold for annoyance, frus...
- Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
Pharmacology
Mechanism of Action
Metizolam is a positive allosteric modulator of GABA-A receptors, binding to the benzodiazepine site at the α-γ subunit interface and potentiating GABA-induced chloride conductance. As a thienodiazepine, its benzene ring is replaced with a thiophene ring, consistent with the broader thienodiazepine class including etizolam and deschloroetizolam.
Structural Relationship
Metizolam relates to diclazepam as etizolam relates to bromazepam — it is the thiophene-ring version of the parent benzodiazepine. Specifically, metizolam is 7-chloro-5-(2-chlorophenyl)-1-methyl-1H-thieno[2,3-e][1,4]diazepin-2(3H)-one, and the thienodiazepine scaffold generally enhances potency relative to the classical benzodiazepine analog.
Potency and Dosing
Community experience suggests metizolam is less potent than etizolam, with active doses in the range of 2–6 mg. This is consistent with the structural difference (absence of etizolam's ethyl triazolo ring extension, which contributes to etizolam's higher binding affinity). The community Reddit post noting "first time metizolam experience, kinda disappointing" following alcohol consumption may reflect relative potency expectations informed by etizolam or other high-potency thienodiazepines.
Pharmacokinetics
Specific pharmacokinetic data are limited. By analogy with related thienodiazepines, onset is expected at 30–60 minutes orally, with peak effects at 1–2 hours and duration of 6–10 hours. The half-life is not well-characterized; structural analysis suggests it is likely intermediate (8–20 hours).
Tolerance
Tolerance develops with regular use through the standard mechanisms of GABA-A receptor downregulation and subunit remodeling, consistent with the broader benzodiazepine class.
Detection Methods
Standard Drug Panel Inclusion
Metizolam is NOT detected on standard drug panels. As a thienodiazepine analogue structurally related to etizolam, it contains the thiophene ring system that prevents recognition by conventional benzodiazepine immunoassay antibodies. Standard 5-panel, 10-panel, and extended drug screens will produce negative results for metizolam regardless of dose consumed.
Urine Detection
Pharmacokinetic data for metizolam is limited. Based on its structural relationship to etizolam and available case reports, urine detection windows are estimated at 2 to 4 days after a single dose. The compound likely undergoes hepatic metabolism via hydroxylation and glucuronidation pathways similar to etizolam. Reliable detection requires LC-MS/MS methods specifically targeting metizolam and its predicted metabolites.
Blood and Serum Detection
Blood detection windows are estimated at 1 to 2 days. The half-life of metizolam is shorter than etizolam, estimated at 2 to 4 hours, leading to rapid clearance from the bloodstream. Active blood concentrations are in the low nanogram range. Forensic case reports are the primary source of blood concentration data.
Hair Follicle Detection
Hair follicle testing for metizolam has not been widely validated. LC-MS/MS methods with appropriate reference standards would be required for detection, with expected windows of up to 90 days.
Confirmatory Methods
LC-MS/MS is required for definitive confirmation. The compound must be specifically added to the analytical panel, as it does not appear on standard benzodiazepine or designer drug confirmation panels. Reference standards are available from specialized forensic chemistry suppliers.
Reagent Testing
No established reagent testing protocols exist for metizolam. The thienodiazepine structure may produce faint responses with the Zimmermann reagent, but these reactions are not diagnostic. Fentanyl test strips should be used on any product suspected to contain metizolam.
Interactions
| Substance | Status | Note |
|---|---|---|
| 1,4-Butanediol | Dangerous | Combined CNS depression; risk of respiratory failure |
| 2M2B | Dangerous | Combined CNS depression; risk of respiratory failure |
| Acetylfentanyl | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Alcohol | Dangerous | Combined CNS depression; risk of respiratory failure |
| Alprazolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Atropa belladonna | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Baclofen | Dangerous | Combined CNS depression; risk of respiratory failure |
| Benzodiazepines | Dangerous | Combined CNS depression; risk of respiratory failure |
| Buprenorphine | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Cake | Dangerous | Combined CNS depression; risk of respiratory failure |
| Carisoprodol | Dangerous | Combined CNS depression; risk of respiratory failure |
| Clonazepam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Clonazolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Clonidine | Dangerous | Combined CNS depression; risk of respiratory failure |
| Codeine | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Datura | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Deschloroetizolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Desomorphine | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Dextropropoxyphene | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Diazepam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Diclazepam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Dihydrocodeine | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Diphenhydramine | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Eszopiclone | Dangerous | Combined CNS depression; risk of respiratory failure |
| Ethylmorphine | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Etizolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| F-Phenibut | Dangerous | Combined CNS depression; risk of respiratory failure |
| Fentanyl | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Flualprazolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Flubromazepam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Flubromazolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Flunitrazepam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Flunitrazolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Gabapentin | Dangerous | Combined CNS depression; risk of respiratory failure |
| Gaboxadol | Dangerous | Combined CNS depression; risk of respiratory failure |
| GBL | Dangerous | Combined CNS depression; risk of respiratory failure |
| GHB | Dangerous | Combined CNS depression; risk of respiratory failure |
| Grayanotoxin | Dangerous | Combined CNS depression; risk of respiratory failure |
| Harmala alkaloid | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Heroin | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Hydrocodone | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Hydromorphone | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Kratom | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Lorazepam | Dangerous | Combined CNS depression; risk of respiratory failure |
| MAOI | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Mephenaqualone | Dangerous | Combined CNS depression; risk of respiratory failure |
| Methadone | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Methaqualone | Dangerous | Combined CNS depression; risk of respiratory failure |
| Midazolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Mirtazapine | Dangerous | Combined CNS depression; risk of respiratory failure |
| Morphine | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Myristicin | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Naloxone | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Nicotine | Dangerous | Combined CNS depression; risk of respiratory failure |
| Nifoxipam | Dangerous | Combined CNS depression; risk of respiratory failure |
| O-Desmethyltramadol | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Oxycodone | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Oxymorphone | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Peganum harmala | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Pentobarbital | Dangerous | Combined CNS depression; risk of respiratory failure |
| Pethidine | Dangerous | Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths |
| Phenobarbital | Dangerous | Combined CNS depression; risk of respiratory failure |
| SAMe | Dangerous | Combined CNS depression; risk of respiratory failure |
| 2-Aminoindane | Caution | Masks the effects of each drug; risk of overdosing when one wears off before the other |
| 2-FA | Caution | Masks the effects of each drug; risk of overdosing when one wears off before the other |
| 2-FEA | Caution | Masks the effects of each drug; risk of overdosing when one wears off before the other |
| 2-Fluorodeschloroketamine | Caution | Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression |
| 2-FMA | Caution | Masks the effects of each drug; risk of overdosing when one wears off before the other |
| 1,3-Butanediol | Low Risk & Decrease | Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers |
| 1B-LSD | Low Risk & Decrease | Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers |
| 1cP-AL-LAD | Low Risk & Decrease | Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers |
| 1cP-LSD | Low Risk & Decrease | Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers |
| 1cP-MiPLA | Low Risk & Decrease | Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers |
History
Research Chemical Market
Metizolam emerged in research chemical markets in the early-to-mid 2010s as part of the broad proliferation of novel benzodiazepines and thienodiazepines during this period. It was developed in the context of the cat-and-mouse regulatory dynamic characteristic of novel psychoactive substance markets — new structural analogs appearing as earlier compounds were scheduled.
Community Discourse
The eight Reddit posts in the database represent a modest but meaningful body of community experience. The range of assessments — from enthusiastic to dismissive — likely reflects genuine pharmacological variability in experience, possibly related to individual differences in hepatic metabolism of thienodiazepines, or expectations set by other benzodiazepine experiences.
Regulatory Status
Metizolam has been subject to varying regulatory actions across jurisdictions, typically grouped with other designer benzodiazepines in blanket scheduling orders in Europe and classified under analogue act provisions elsewhere. Its legal status continues to evolve.
Harm Reduction
No Alcohol Combinations
Community reports include at least one user who combined metizolam with alcohol and found effects disappointing. The appropriate lesson is not that the combination is safe — rather, CNS depressant synergy significantly increases respiratory depression risk regardless of subjective effect quality.
Moderate Frequency of Use
Standard benzodiazepine harm reduction applies: use no more than twice weekly to reduce tolerance and dependence liability, with extended breaks.
Realistic Dose Calibration
Community accounts describe variable effects, with some users finding it underwhelming at expected doses. Avoid the temptation to significantly escalate dose in response to perceived lack of effect — the CNS depression may be present even when euphoric or anxiolytic effects are modest.
Accurate Measurement
Milligram-accurate dosing is required, especially for a compound where dose-response curves are not well established.
Taper Protocol If Dependent
Standard benzodiazepine taper protocols apply. Switch to an equivalent long-acting benzodiazepine if available, or reduce dose by 5–10% per week under medical supervision.
Toxicity & Safety
Class Risk Profile
Metizolam carries the standard benzodiazepine toxicity profile. Sole-agent use at typical doses is unlikely to be directly fatal in otherwise healthy individuals, but the combination with alcohol or opioids substantially elevates respiratory depression risk.
Physical Dependence and Withdrawal
Regular use produces physical dependence. The thienodiazepine class does not confer any special protection against the potentially fatal withdrawal syndrome of GABAergic CNS depressants. Abrupt cessation after prolonged daily use can produce:
Combination with Alcohol (from Database Reports)
At least one experience report documents metizolam use following alcohol consumption. This combination increases CNS depression and respiratory depression risk. The subjective disappointment reported in that account should not be interpreted as evidence of low risk from this combination.
Limited Characterization
Like all research chemical benzodiazepines, the absence of formal clinical trials means dosing guidance is derived from community reports with inherent variability. Dose-response characterization is incomplete.
Addiction Potential
extremely addictive
Overdose Information
overdose can be lethal when mixed with other depressants including alcohol or opioids.
It is strongly recommended that one use harm reduction practices when using this substance. -extremely addictive. Tolerance to the sedative-within a couple of days of repeated administration. After that,3 - 71 - 2 weeks to be back at baseline (in the absence of further consumption). Metizolam presents cross-tolerance with Cross-all thienzodiazepines and benzodiazepines, meaning that after the consumption of metizolam all compounds of the same class will have a reduced effect.
Abrupt discontinuation of metizolam following regular dosing over several days can result in a withdrawal phase which includes rebound symptoms such as increased anxiety and insomnia. It is possible to gradually reduce the dose over the course of several days, which will lengthen the duration of the withdrawal period, but reduce the perceived intensity.
Thienzodiazepine discontinuation is notoriously difficult; it is potentially life-threatening for individuals using regularly to discontinue use without tapering their dose over a period of weeks. There is an increased risk of seizure following discontinuation. Drugs which lower the seizure threshold such as tramadol should be avoided during withdrawal.
- Overdose
Thienodiazepine overdose may occur when a thienodiazepine is taken in extremely heavy quantities or concurrently with other depressants. This is particularly dangerous with other GABAergic depressants such as barbiturates and alcohol since they work in a similar fashion, but bind to distinct allosteric sites on the GABAA receptor. Thus their effects potentiate one another. Thienodiazepines increase the frequency in which the chlorine ion pore opens on
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Unpredictable potentiation of CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Unpredictable potentiation of CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Unpredictable potentiation of CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression; this combination is the leading cause of prescription drug overdose deaths
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Tolerance
| Full | within a couple of days of repeated administration |
| Half | 3 - 7 days |
| Zero | 1 - 2 weeks |
Cross-tolerances
Legal Status
Metizolam is currently a grey area compound within most parts of the world. This means that it is not known to be specifically illegal within any country, but people may still be charged for its possession under certain circumstances such as under analogue laws and with intent to sell or consume.
Canada: All benzodiazepines are Schedule IV controlled substances in Canada.
Germany: Metizolam is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Sweden: Following its sale as a designer drug, metizolam was made illegal in Sweden on January 26, 2016.
Switzerland: Metizolam is a controlled substance specifically named under Verzeichnis E.
Turkey:** Metizolam is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom: It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26, 2016.
Responsible use
Volumetric liquid dosing
Thienodiazepine
Benzodiazepine
Metizolam (Wikipedia)
Metizolam (Isomer Design)
Metizolam (Bluelight)
Metizolam (UK Chemical Research)
Experience Reports (1)
Tips (7)
Keep a written log of your Metizolam use including time and dose. Benzodiazepines impair memory formation, making it easy to forget you already dosed and accidentally take more. This is how many accidental overdoses happen.
Like all benzodiazepine analogs, metizolam carries risk of physical dependence with regular use. Never stop abruptly after daily use of more than two weeks. Benzodiazepine withdrawal can cause seizures and be life-threatening.
Metizolam is considered a good entry-level benzodiazepine analog because it is relatively difficult to black out on compared to stronger compounds like clonazolam. It provides anxiolysis without as much sedation.
Metizolam is roughly half the potency of etizolam. If you are familiar with etizolam dosing, double your usual dose as a starting reference point, but always start lower to account for individual variation.
If prescribed Metizolam, use it as directed and have honest conversations with your doctor about any recreational use. Benzodiazepines are among the most difficult drugs to quit once dependent. Short-term use only.
Community opinion on metizolam is polarized. Some find it an excellent functional anxiolytic while others find it underwhelming. Set realistic expectations and do not chase effects by escalating doses, as this leads to dependence.
Community Discussions (8)
See Also
References (3)
- PubChem: Metizolam
PubChem compound page for Metizolam (CID: 12434325)
pubchem - Metizolam - TripSit Factsheet
TripSit factsheet for Metizolam
tripsit - Metizolam - Wikipedia
Wikipedia article on Metizolam
wikipedia